J&J nears the sale of its Ortho clinical Dx division, and other big news from the holidays

FierceMedicalDevices resumes Monday-Friday email newsletter publication today after a nice holiday breather. But we kept a close eye on med tech news in the interim. Below, we've provided links to those stories you may have missed while you were away. Click away and catch up, and, as always, thanks for reading.

- Myriad ($MYGN) braces for a direct hit with CMS set to slash BRCA Dx test payments. Story

- Abbott ($ABT) forks over $5.5M to settle physician kickback allegations. Story

- MC10 grabs $19.8M more to advance stretchable sensors for med tech. Story

- Intuitive Surgical's ($ISRG) robot surgery injuries went unreported for years, report says. Story

- Stryker ($SYK) director (and founder's granddaughter) sells a pile of shares. Story

- Boston Scientific ($BSX) plots a major China expansion in the months to come. Story

- Report: J&J ($JNJ) wants Carlyle to snatch up its Ortho Clinical Diagnostics arm. Story

- Mederi draws $18.5M Series B to expand reach of GI treatment devices. Story

- Intact raises $4.7M to further its PAD device work. Story

- Carmat's (so far) successful human artificial heart transplant shoots stock higher. Story

-- Mark Hollmer (email | Twitter)

Suggested Articles

In an SEC filing, Baxter International disclosed that it may have overstated its income over multiple years, inflating it by about $276 million.

The FDA has given Grail a green light to conduct the interventional study, and it has begun enrolling participants through the company’s R&D partners.

Coronavirus may not require a front-line battle yet in certain places, but it’s still taxing public health officials preparing for a potential crisis.